Welcome to our dedicated page for Pharmadrug news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.
PharmaDrug Inc. (LMLLF) provides investors and industry stakeholders with essential updates through this centralized news repository. Our curated collection focuses on material developments in biosynthetic pharmaceutical manufacturing, clinical research advancements, and strategic partnerships within the specialty pharmaceuticals sector.
Access verified corporate disclosures including regulatory filings, manufacturing process patents, and subsidiary developments. Key coverage areas include GMP-compliant production milestones, natural medicine reformulation progress, and controlled substance research updates aligned with harm reduction initiatives.
This resource serves as a definitive source for tracking PharmaDrug's progress in pharmaceutical-grade substance development. Users will find official communications regarding technology licensing agreements, clinical trial authorizations, and intellectual property expansions within the biosynthetic chemistry domain.
Bookmark this page for direct access to original press releases and SEC filings. For comprehensive understanding of PharmaDrug's position in specialty pharmaceuticals, we recommend reviewing updates regularly and consulting official regulatory documents for complete context.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) has announced that its 51%-owned subsidiary, Sairiyo Therapeutics, received approval on August 12, 2024, to initiate a Phase 1 clinical trial for PD-001, a patented reformulated enteric coated version of oral cepharanthine. The study, approved by the Australian Human Research Ethics Committee, will investigate PD-001 as a potential treatment for Medical Countermeasures and cancer.
PD-001 previously received a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for Ebola virus research. The Phase 1 trial will assess the bioavailability and pharmacokinetics of 15 mg and 30 mg capsules of PD-001 compared to 15 mg oral cepharanthine tablets in healthy volunteers. Upon completion, Sairiyo plans to submit an Investigational New Drug application to the FDA for Phase 2 and 3 trials in the United States.
PharmaDrug's subsidiary, SecureDose, has signed a Letter of Intent (LOI) with a Canadian licensed drug dealer to manufacture pharmaceutical grade cocaine. This LOI, signed on May 16, 2024, allows SecureDose to initiate technology transfer for its patented cocaine synthesis method, aiming for a full manufacturing and distribution agreement. The partnership marks a strategic step to produce commercial-scale cocaine batches for safe supply programs. PharmaDrug aims to contribute to harm reduction by offering a regulated, biosynthetic alternative to contaminated street drugs.
PharmaDrug's Sairiyo Therapeutics has filed a clinical trial application with the Australian Human Research Ethics Committee for a Phase 1 study of its patented reformulated cepharanthine (PD-001). This study will evaluate the bioavailability and pharmacokinetics of 30 mg and 60 mg enteric-coated capsules compared to 6 mg tablets in healthy volunteers. If approved in June 2024, this trial will be the first human test of PD-001, aimed at treating infectious diseases and oncology. Sairiyo's Australian subsidiary will sponsor the study. The initiative leverages Australia's drug development incentives, offering a 43.5% tax rebate. Successful completion may lead to FDA applications for further trials in the U.S.
PharmaDrug Inc. (CSE: PHRX) provides an update on its patent-pending biosynthetic cocaine manufacturing process, focusing on commercialization and safe supply programs. CEO Robert Steen outlines the strategic plan to accelerate commercialization, engage in global partnerships, and streamline regulatory processes. The company aims to deliver pharmaceutical-grade cocaine to meet increasing demand, with a focus on innovative production methods and market distribution for 2024.
PharmaDrug Inc. announces the appointment of Zalman Goldman to its board of directors, with a background in addiction and recovery, to advance the company's mission in drug research and commercialization. Concurrently, Nickolai Vassev resigns from the board. Mr. Goldman brings valuable experience to the company, receiving 500,000 stock options as part of his appointment.
PharmaDrug's Sairiyo Therapeutics has finished the clinical and regulatory package for a Phase 1 study of their reformulated cepharanthine in Australia. This patented drug, PD-001, aims to treat infectious diseases and oncology. Sairiyo will conduct the study in Australia to benefit from drug development incentives, planning to submit an Investigational New Drug application to the FDA afterward.
FAQ
What is the current stock price of Pharmadrug (LMLLF)?
What is the market cap of Pharmadrug (LMLLF)?
